NCT06671379View on ClinicalTrials.gov

A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC

PHASE3RecruitingINTERVENTIONAL

Enrollment

500

Participants

Timeline

Start Date

November 29, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

SHR-A2009 monotherapy

SHR-A2009 monotherapy ，SHR-A2009 will be administered intravenously

DRUG

platinum-based dual-agent chemotherapy

Pemetrexed combined with carboplatin or cisplatin, after four cycles of combination, pemetrexed was continued as a single agent，all drugs will be administered intravenously

Trial Locations (1)

510000

RECRUITING

Guangdong Provincial People's Hospital, Guangzhou

All Listed Sponsors

lead

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

INDUSTRY

NCT06671379 - A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC | Biotech Hunter | Biotech Hunter